Abeona Therapeutics

In August 2014, Norgine entered into a license agreement with PlasmaTech Biopharmaceuticals Inc. to develop and commercialise the medical device, MUGARD® in Europe for the prevention and management of the lesions and symptoms of oral mucositis. 


In October 2014, Norgine B.V signed expanded licensing agreement with PlasmaTech Biopharmaceuticals for MUGARD® to now include Australia and New Zealand.